CVE:ZOM Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM) Stock Price, News & Analysis → They say it’s ‘unstoppable’ – How I made 43,509% (From Investing Daily) (Ad) Free ZOM Stock Alerts C$0.28 -0.02 (-6.56%) (As of 02/5/2020) Add Compare Share Share Today's RangeC$0.29▼C$0.2950-Day RangeC$0.29▼C$0.2952-Week RangeC$0.29▼C$1.50Volume4,800 shsAverage Volume2,858 shsMarket CapitalizationC$36.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Zomedica Pharmaceuticals Corp. (ZOM.V) alerts: Email Address Ad Investing DailyThey say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Zomedica Pharmaceuticals Corp. (ZOM.V) Stock (CVE:ZOM)Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. Its lead drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was founded in 2015 and is headquartered in Ann Arbor, Michigan.Read More ZOM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ZOM Stock News HeadlinesNovember 19, 2023 | morningstar.comZomedica Corp Ordinary Shares ZOMMay 10, 2023 | benzinga.comZomedica Stock (AMEX:ZOM), DividendsApril 27, 2024 | Investing Daily (Ad)They say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.May 8, 2023 | msn.comZomedica acquires Structured Monitoring ProductsMarch 15, 2023 | seekingalpha.comZomedica expands topline thanks to acquisitions and organic growthJanuary 25, 2023 | seekingalpha.comSquarex Pharmaceutical Seeks IPO For Development FundingJanuary 19, 2023 | marketwatch.comAdvanced Therapy Medicinal Products Market Detailed Analysis of Current Scenario with Growth Forecasts to 2029January 15, 2023 | marketwatch.comPulmonary Edema Treatment Market Opportunities, Demand and Forecasts 2023-2028 with Top Countries DataApril 27, 2024 | Investing Daily (Ad)They say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.January 9, 2023 | benzinga.comCorporate Reputation of Pharma in United States, 2021-2022: The Patient Perspective of 40+ Companies 2021 v. 2020December 14, 2022 | wsj.comHPGC Renmintongtai Pharmaceutical Corp. ADecember 14, 2022 | marketwatch.comRespiratory Devices Market 2023 To Garner Overwhelming Hike In Revenues by 2026 | 132 Pages ReportNovember 2, 2022 | msn.comCVS Health raises annual profit forecast on strength in PBM, insurance unitsOctober 6, 2022 | yahoo.comMicrobion Corporation Announces Granting of a US Patent for a Pharmaceutical Composition of PravibismaneOctober 1, 2022 | reuters.com001067F.KSSeptember 30, 2022 | wsj.comSaudi Pharmaceutical Industries & Medical Appliances Corp.September 15, 2022 | finance.yahoo.comNova Mentis Completes Production of Psilocybin Microdose CapsulesSeptember 7, 2022 | finance.yahoo.comGlobal Counterfeit Drug Detection Devices Market Valuation to Exceed $1.3 Billion by 2026September 7, 2022 | finance.yahoo.comCipla receives USFDA approval for generic version of Revlimid® (Lenalidomide capsules)August 12, 2022 | finance.yahoo.comEupraxia Pharmaceuticals Reports Second Quarter 2022 Financial ResultsAugust 8, 2022 | benzinga.comPsychedelic Drugs Global Market to Reach $7.03 Billion by 2026July 15, 2022 | finance.yahoo.comInsights on the Veterinary Medicine Global Market to 2027 - by Product, Animal Type, Route of Administration, Distribution Channel and RegionJuly 11, 2022 | finance.yahoo.comDilated Cardiomyopathy Market to Boost at a CAGR of approximately 13% by 2032 | DelveInsightJune 29, 2022 | finance.yahoo.comGlobal Decentralized Clinical Trials Market is projected to grow at a CAGR of 6.95% By 2032: Visiongain Reports LtdJune 10, 2022 | apnews.comThe Worldwide Pharmacovigilance Industry is Expected to Reach $15.8 Billion by 2030 - ResearchAndMarkets.comApril 8, 2022 | msn.comAnnapolis Area Job Openings: Check Out The LatestFebruary 20, 2022 | nz.finance.yahoo.comPacerPro Director of Design Releases First in a Series of New Product EnhancementsSee More Headlines Receive ZOM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zomedica Pharmaceuticals Corp. (ZOM.V) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:ZOM CUSIPN/A CIKN/A Webwww.zomedica.com Phone734-369-2555FaxN/AEmployees27Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio4.91 Current Ratio15.31 Quick Ratio15.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.05 per share Price / Cash Flow5.38 Book ValueC$0.05 per share Price / Book5.82Miscellaneous Outstanding Shares128,872,000Free FloatN/AMarket CapC$36.73 million OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Gerald L. Solensky Jr. (Age 45)Chairman, Pres & CEO Mr. Shameze Rampertab B.Sc. MBA (Age 52)CA, CPA, CFO, Corp. Sec. & Director Dr. Stephanie Morley D.V.M. (Age 44)DVM, COO & VP of Product Devel. Mr. Michael SchilkVP of SalesMr. David EatonVP of MarketingKey CompetitorsViridium Pacific GroupCVE:VIRInMed PharmaceuticalsTSE:INMeta GrowthCVE:METAMedexus PharmaceuticalsTSE:MDPMediPharm LabsTSE:LABSView All Competitors ZOM Stock Analysis - Frequently Asked Questions How have ZOM shares performed in 2024? Zomedica Pharmaceuticals Corp. (ZOM.V)'s stock was trading at C$0.29 at the start of the year. Since then, ZOM stock has increased by 0.0% and is now trading at C$0.29. View the best growth stocks for 2024 here. What other stocks do shareholders of Zomedica Pharmaceuticals Corp. (ZOM.V) own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zomedica Pharmaceuticals Corp. (ZOM.V) investors own include Heat Biologics (HTBX), Biocept (BIOC), Remark (MARK), Onconova Therapeutics (ONTX), Vislink Technologies (VISL), Genius Brands International (GNUS), Ritter Pharmaceuticals (RTTR), T2 Biosystems (TTOO), Guardion Health Sciences (GHSI) and MicroVision (MVIS). How do I buy shares of Zomedica Pharmaceuticals Corp. (ZOM.V)? Shares of ZOM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:ZOM) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyHe Is Giving Away BitcoinCrypto Swap ProfitsProtect Your Bank Account Before It’s Too LateWeiss RatingsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zomedica Pharmaceuticals Corp. (ZOM.V) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
